Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

By D. Oh, A. Ruth He, S. Qin, Li‐Tzong Chen, T. Okusaka, A. Vogel, J. W. Kim, T. Suksombooncharoen, Myung Ah Lee, Masayuki Kitano and 19 more. NEJM Evidence, 2022

864 citations recorded by the source corpus.

Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin. Median overall survival (95% Cl) was 12.8 (11.1-14.0) months in the durvalumab group. Rates of grade 3 or 4 adverse events were similar between groups.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/29f3a04b25b6813fb4cf8cbb169f285f9f85b5e3